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Atovaquone/Proguanil Therapy
for Plasmodium falciparum
and Plasmodium vivax Malaria
in Indonesians Who Lack
Clinical Immunity
Mark D. Lacy,1 Jason D. Maguire,1 Mazie J. Barcus,1 Judith Ling,1,3,a
Michael J. Bangs,1 Robert Gramzinski,1 Hasan Basri,1
Priyanto Sismadi,2 Gerri B. Miller,4 Jeffrey D. Chulay,4,a
David J. Fryauff,5 Stephen L. Hoffman,5,a and J. Kevin Baird1
1Parasitic Diseases Program, US Naval Medical Research Unit 2,
and 2Communicable Diseases, National Institute of Health Research
and Development, Ministry of Health, Republic of Indonesia, Jakarta,
Indonesia; 3Children’s National Medical Center, George Washington University,
Washington, D.C.; 4GlaxoSmithKline, Research Triangle Park, North Carolina;
and 5Malaria Program, Naval Medical Research Center, Silver Spring, Maryland
Thirty-eight of 295 subjects participating in a randomized,
double-blind, placebo-controlled trial of the efficacy of daily
administration of atovaquone/proguanil for malaria preven-
tion developed malaria at some time during the 20-week pro-
phylaxis period. These subjects (3 atovaquone/proguanil re-
cipients and 35 placebo recipients) were treated with 4 tablets
of atovaquone/proguanil per day for 3 days. Atovaquone/pro-
guanil provided safe, well-tolerated, and effective therapy for
uncomplicated malaria in nonimmune Indonesians.
Malaria is the most common life-threatening infectious dis-
ease among travelers. Chemoprophylaxis effectively reduces
the risk of acquiring disease, but many people who could
benefit from chemoprophylaxis do not use it as directed [1].
Each year, 110,000 North American and European people
acquire malaria while traveling abroad, and several hundred
of these people die [2, 3]. Deterioration of the global malaria
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situation during the past 30 years, which has been caused
predominantly by resistance to antimalarial drugs and the
deterioration of vector-control programs in poorer countries
[4, 5], along with the increasing number of travelers, makes
malaria an important health risk for visitors to tropical areas
where malaria is endemic.
Susceptibility to antimalarial drugs often follows distinct
geographical patterns. Confidence in chemotherapy by the phy-
sician who treats patients with malaria may hinge on the pub-
lished record of therapeutic outcomes in regions where infec-
tions are endemic. We describe our clinical experience with a
new antimalarial drug that contains a fixed combination of
atovaquone and proguanil hydrochloride (Malarone; Glaxo-
SmithKline) for the treatment of uncomplicated malaria due
to Plasmodium falciparum and Plasmodium vivax in nonim-
mune adults infected in Papua, the easternmost province of
Indonesia, which occupies the western half of the island of New
Guinea. Four other reports have described the efficacy of ato-
vaquone/proguanil against P. falciparum malaria in Southeast
Asia [6–9], an area notorious for the presence of drug-resistant
malaria. This study also adds to 2 published reports about the
therapeutic efficacy of atovaquone/proguanil against P. vivax
malaria in Southeast Asia [6, 10]. We conducted the study in
an area where most P. vivax strains are resistant to chloroquine
[11, 12].
Subjects and methods. Subjects were treated during the
period of April 1999 through June 2000 in 3 villages (SP4,
SP5, and SP6) that are within a few kilometers of the Pacific
Ocean, along the northeastern coast of Papua (formerly Irian
Jaya), Indonesia. Subjects had participated in a randomized,
placebo-controlled trial of atovaquone/proguanil that is re-
ported elsewhere [13]. In brief, we enrolled Javanese adults
who were considered to lack clinical immunity to malaria on
the basis of life-long residence in nonmalarious areas before
migration to Papua. Before they started receiving prophylaxis,
all subjects received directly observed curative therapy with
1 g of atovaquone and 400 mg of proguanil hydrochloride
per day for 3 days, followed by 2 tablets of primaquine phos-
phate (Sanofi Winthrop; 15 mg base per tablet) daily for 14
days. After they received curative therapy, subjects immedi-
ately began taking daily doses of either prophylactic medi-
cation (atovaquone, 250 mg, and proguanil hydrochloride, 100
mg) or matching placebo (1:1 randomization) for up to 20
weeks. During the prophylaxis period, microscopic examina-
tion of Giemsa-stained thick blood films was performed weekly
or any time a subject complained of experiencing symptoms
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Table 1. Demographic and clinical characteristics of subjects receiving atovaquone/proguanil therapy




( )n p 19
Plasmodium vivax–
infected subjects
( )n p 16
Subjects with
mixed infection
( )n p 3
Sex, no. male/no. female 16/3 13/3 3/0
Weight, mean kg 54.5 50.9 50.8
Age, mean years (range) 37.1 (15–60) 32.8 (15–48) 25.7 (20–33)
Febrile subjects, % 79a 44 100
Symptomatic subjects, % 96 75 100
Asexual parasitemia, mean
no. of parasites/mL (range) 3238 (80–32,360) 451 (40–10,400) 3460 (2480–5880) for P. fal-
ciparum; 404 (80–1720)
for P. vivax
a When the P. falciparum–infected group and the mixed-infection group were combined, 82% of the subjects were febrile.
consistent with malaria. Subjects with slide-confirmed malaria
during the prophylaxis period constituted the treatment pop-
ulation reported here.
Confirmation of asexual parasitemia by 2 expert microsco-
pists prompted the administration of directly observed therapy
with atovaquone/proguanil (atovaquone, 1 g, and proguanil,
400 mg, q.d. for 3 days) 24 h after the initial diagnosis.
Posttherapy follow-up consisted of monitoring the subject’s
temperature (via the ear canal) and examining blood films on
days 1–7, 14, 21, and 28 after the initiation of therapy. Subjects
infected with P. vivax also received 30 mg of primaquine per
day for 14 days immediately after they completed atovaquone/
proguanil therapy.
Results. During the prophylaxis period, 40 subjects de-
veloped malaria (37 while receiving placebo and 3 while re-
ceiving atovaquone/proguanil) 20–140 days after they started
receiving prophylaxis [13]. Two subjects from the placebo
group were excluded from the analysis of therapy (one because
of vomiting that required intravenous quinine therapy, and the
other because of a breach of treatment protocol). Atovaquone/
proguanil therapy was administered to 19, 16, and 3 patients
with P. falciparum, P. vivax, or mixed infections, respectively.
The geometric mean parasite counts at the time of diagnosis
were 3238 parasites/mL (range, 80–32,360 parasites/mL) for sub-
jects with P. falciparum malaria and 451 parasites/mL (range,
40–10,400 parasites/mL) for subjects with P. vivax malaria.
Table 1 summarizes the demographic and clinical charac-
teristics of treated subjects. Subjects were predominantly young
adult men, which reflects the demographic characteristics of
the population recruited for the prophylaxis study [13]. One
or more of the following symptoms was considered to be con-
sistent with clinical disease caused by malaria: fever, chills, head-
ache, nausea, abdominal pain, arthralgias, myalgias, and mal-
aise. Clinical disease was more common for P. falciparum
infection than for P. vivax infection. Fever occurred in 18 (82%)
of 22 subjects infected with P. falciparum (including 3 mixed-
species infections) and in 7 (44%) of 16 subjects infected with
P. vivax (excluding mixed infections). At least 1 symptom of
malaria occurred in 21 (96%) of 22 subjects infected with P.
falciparum and in 12 (75%) of 16 subjects infected with P. vivax.
All subjects completed therapy without interruption. Only 1
subject had an adverse event that was possibly attributable to
therapy. A 37-year-old man with P. falciparum malaria devel-
oped abdominal pain 24 h after he completed therapy. No
specific cause was identified, and he recovered fully after 1 day
without requiring medical intervention.
All subjects had a prompt clinical and parasitological re-
sponse to treatment with atovaquone/proguanil. Fever re-
solved after a mean of 1.5 days (range, 0–3 days) among
subjects with P. falciparum malaria and 0.8 days (range, 0–4
days) among subjects with P. vivax malaria (figure 1, bottom).
Parasitemia resolved after a mean of 2.7 days (range, 1–4 days)
among subjects with P. falciparum malaria and 2.5 days
(range, 1–3 days) among subjects with P. vivax malaria (figure
1, top). For the 3 subjects who developed parasitemia while
taking atovaquone/proguanil prophylaxis (2 had P. vivax in-
fection and 1 had a mixed infection), parasitemia did not
recur during the 4-week follow-up period. Among the 35
subjects who developed parasitemia while taking placebo, 1
subject had recurrent P. falciparum parasitemia on day 21. A
second subject treated for P. falciparum malaria developed P.
vivax parasitemia on day 28.
Discussion. We evaluated atovaquone/proguanil therapy
in 38 subjects with acute, uncomplicated malaria caused by P.
falciparum and/or P. vivax in Papua, Indonesia. Atovaquone/
proguanil therapy was safe, effective, and well tolerated in these
subjects. All subjects completed the regimen, and only 1 subject
experienced an adverse event (moderate abdominal pain) that
may have been related to therapy.
All subjects had prompt clearance of fever and parasitemia,
and 21 (96%) of the 22 subjects with P. falciparum malaria did
not have recurrent parasitemia during the 28-day follow-up
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Figure 1. Parasitological and clinical response to treatment with ato-
vaquone/proguanil for uncomplicated malaria in Papua, Indonesia. Top,
Geometric mean parasite count for Plasmodium falciparum and Plas-
modium vivax during the week after the start of therapy. Bottom, Per-
centage of subjects infected with P. falciparum or P. vivax who had
documented fever during the week after the start of therapy.
period. In 1 subject, recurrent P. falciparum parasitemia on day
21 could have been due to recrudescence (RI response [14])
or reinfection. Attempts to distinguish between these possibil-
ities by genotyping of PCR-amplified parasite DNA from sam-
ples obtained before treatment and at the time of recurrence
were not successful.
No evidence of clinical resistance to atovaquone/proguanil
therapy appeared among the 3 subjects for whom atovaquone/
proguanil prophylaxis failed. This suggests that these prophy-
laxis failures were related to factors other than drug-resistant
parasites. The high efficacy of atovaquone/proguanil for the
treatment of uncomplicated malaria caused by P. falciparum in
this study corroborates the findings of other reports from
Southeast Asia [6–9].
The 19 subjects with parasitemia due only to P. falciparum
did not receive primaquine, and 1 of these subjects developed
P. vivax parasitemia on day 28 after initiating treatment with
atovaquone/proguanil. Because subjects in this study were con-
tinually exposed to malaria-infected mosquitoes, the parasi-
temia could have been a delayed primary episode resulting from
an infection that occurred shortly before rescue treatment was
initiated, or it could have been a posttreatment episode re-
sulting from an infection that occurred shortly after the rescue
treatment regimen was finished.
On the basis of previous studies that have indicated that
atovaquone/proguanil has little or no effect on hypnozoites of
P. vivax (the latent liver-stage parasites responsible for relapse),
in our study, therapy for P. vivax malaria included a 30-mg
primaquine base given daily for 14 days after the completion
of atovaquone/proguanil treatment. One previous study of ato-
vaquone/proguanil for the treatment of P. vivax malaria that
did not include primaquine reported that 14 (74%) of 19 sub-
jects had recurrent P. vivax infection 16–26 days after initiating
therapy [6]. In another study, 30 mg of primaquine was given
daily for 14 days after the completion of atovaquone/proguanil
therapy; all 42 subjects who were still being observed at day 28
remained free of parasitemia. Two of those subjects had re-
current parasitemia at day 56, indicative of relapse. In our study,
all 19 subjects with P. vivax malaria had prompt clearance of
fever and parasitemia, and none had recurrent parasitemia dur-
ing the 28-day follow-up period. In previous studies from this
region that have included primaquine therapy, recurrent P. vi-
vax parasitemia occurred in 15% of the subjects treated with
chloroquine [12]. Given the high risk of therapeutic failure
with chloroquine against P. vivax in Papua (150%), our findings
suggest that treatment with atovaquone/proguanil for 3 days,
followed by primaquine for 14 days, may be an effective al-
ternative to chloroquine for patients with chloroquine-resistant
P. vivax malaria.
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